ライフサイエンスコーパス: betaxolol

1 sts, like clonidine, are very different from betaxolol.

2 tion of [Ca2+]i was significantly reduced by betaxolol.

3 I-118,551, but not the beta-1 AR antagonist, betaxolol.

4 antagonist alprenolol or the inverse agonist betaxolol.

5 terenol in the order timolol > propranolol > betaxolol.

6 1.85; 3.13), brinzolamide 2.42 (1.62; 3.23), betaxolol 2.24 (1.59; 2.88), and unoprostone 1.91 (1.15;

7 By contrast, betaxolol (20 mg p.o.), a selective beta1-antagonist dev

8 It is thought that betaxolol, a beta(1)-adrenoceptor antagonist, acts as a

9 Betaxolol, a selective beta(1)-adrenoceptor antagonist,

10 d from 6.19 to 23.53 microM, indicating that betaxolol acts as a non-competitive inhibitor of glutama

11 experiments provide supporting evidence that betaxolol acts in a manner consistent with preventing re

12 mine whether i.p. injections of clonidine or betaxolol affect retinal bFGF mRNA levels.

13 Nifedipine, flunarizine, and betaxolol all reduced the NMDA-induced influx of calcium

14 energic antagonist timolol, propranolol, and betaxolol also inhibited Na+, K+, Cl- cotransport stimul

15 he mean IOP for the experimental eyes in the betaxolol and apraclonidine groups was lower than that i

16 he experimental eyes of animals administered betaxolol and apraclonidine were 29 +/- 7 and 29 +/- 4 m

17 The fact that both betaxolol and clonidine blunt hypoxia-induced death to r

18 the beta1 and beta2 NE receptor antagonists betaxolol and ICI 118551 or vehicle into the CeA or BNST

19 nolol), and beta(1)- and beta(2)-antagonist (betaxolol and ICI-118,551 HCl).

20 Flunarizine was more effective than betaxolol and much stronger than nifedipine at attenuati

21 ta are consistent with previous reports that betaxolol and other beta-adrenergic blockers may exert i

22 sent study, we examined the effectiveness of betaxolol and other beta-adrenergic blockers on glutamat

23 s study, the beta(2)- (ICI-18551), beta(1)- (betaxolol) and mixed beta(1)/beta(2)- (timolol, metipran

24 ge-clamp conditions was reduced by 50 microM betaxolol, and the difference current-voltage (I-V) rela

25 to block the sympathetic nervous system and betaxolol as a control agent in independent test session

26 ctiveness of flunarizine with nifedipine and betaxolol at reducing the influx of calcium or sodium.

27 oxy]-2-propanolmethanesulfonate (CGP20712A), betaxolol, bisoprolol, and metoprolol.

28 an alpha1-(prazosin) and beta1-adrenoceptor (betaxolol) blocker but not by a selective 5-HT1A blocker

29 Betaxolol compressed the dose-response curve of glutamat

30 Prazosin and betaxolol did not have a nonspecific reducing action on

31 AM beta2-adrenoceptor levels, treatment with betaxolol did not significantly alter levels of the G pr

32 reover, i.p. injection of clonidine, but not betaxolol, elevated bFGF mRNA levels in the retina.

33 of inhibitory potency is (s)(-)-propranolol>betaxolol>>timolol, with average IC(50) of 78.05, 235.7

34 Therefore, betaxolol has the potential to be a neuroprotective agen

35 medications (prednisolone acetate [generic], betaxolol HCl [Betoptic; Alcon Laboratories Inc., Fort W

36 the selective beta1-adrenoceptor antagonist betaxolol hydrochloride (30 microM), the facilitating ef

37 ive in reducing drug-seeking on ED1, whereas betaxolol/ICI-118 551 was ineffective.

38 g seeking on ED1, and WAY100635/GR127935 and betaxolol/ICI-118 551 were each partially effective.

39 lls are long (15-35 minutes for 20-50 microM betaxolol), indicative of modulation through slow bioche

40 The combined data show that betaxolol is a neuroprotective agent and attenuates the

41 he aim of the study was to determine whether betaxolol is a neuroprotective agent and can therefore s

42 te that the up-regulation of the receptor by betaxolol is likely to reflect an increase in translatio

43 The physiological actions of betaxolol lead to reducing neurotoxic effects in ganglio

44 Betaxolol-mediated up-regulation of the CAM beta2-adreno

45 a either to argon laser trabeculoplasty plus betaxolol (n = 129) or to no immediate treatment (n = 12

46 ons of either artificial tears (n = 6), 0.5% betaxolol (n = 5), or 0.5% apraclonidine (n = 5) were de

47 After sustained treatment with betaxolol, Northern analyses did not demonstrate up-regu

48 The times-to-action of betaxolol on ganglion cells are long (15-35 minutes for

49 Inclusion of betaxolol partially prevented the changes caused by NMDA

50 s GR127935 (5-HT1A/1B receptor antagonists), betaxolol plus ICI-118 551 (beta1 and beta2 antagonists)

51 Betaxolol reduced Fin by 0.075 +/- 0.021 muL/min (P = 0.

52 Bath application of 20 microM betaxolol reduced the glutamate-induced increase of spon

53 ls harboring the CAM beta2-adrenoceptor with betaxolol resulted in a large (4-7-fold within 24 hr) up

54 Application of 50 microM betaxolol reversibly reduced the voltage-gated sodium an

55 eta2-adrenoceptor required concentrations of betaxolol similar to those needed to cause half-maximal

56 In contrast, with the control agent betaxolol, there was no increase.

57 Betaxolol, up to 100 microM, exerted no effects on horiz

58 enzyme was almost completely attenuated when betaxolol was included in the culture medium.

59 When betaxolol was injected i.p. into the rats before ischaem

60 to alprenolol, and a much smaller effect of betaxolol was produced in cells expressing the wild-type

61 Betaxolol was tested to see whether it can attenuate the

62 the isolated retina or cortical neurons, but betaxolol was the least effective.

63 current-voltage (I-V) relation (I(Control)-I(betaxolol)) was N-shaped and AP5-sensitive, characterist